The EACH Coalition submitted letters to the Maryland PDAB ahead of expected cost reviews of the two drugs Jardiance and Farxiga.
The letters highlight the limitations of UPLs to create savings for patients and outline the risk that patient access to these and similar medications in the class could be compromised due to increased utilization management.